Defence Valuations 'Obnoxious' While Private Banks Show Strong Potential

Market expert Sandip Sabharwal has issued a stark warning to investors chasing the recent defence rally, suggesting that many stock prices have decoupled from fundamental reality. While certain sectors like private banking appear poised for a structural turnaround, others face significant valuation risks and looming headwinds.

Defence: Caution Amidst "Obnoxious" Valuations

The defence sector has been a primary driver of recent market enthusiasm, but Sabharwal warns that the excitement has pushed valuations to unsustainable levels. He specifically flagged the small-cap private defence space, describing price-to-earnings (P/E) ratios ranging from 100 to 200 times as "obnoxious" and unjustified.

Despite the broad warning, there are pockets of stability. Sabharwal remains bullish on Bharat Electronics (BEL), citing strong order books and the increasing demand for Indian-made products in overseas markets. Regarding Hindustan Aeronautics Ltd (HAL), he noted that while it is no longer expensively valued following recent corrections, operational inefficiencies remain a key concern for investors to watch. He also highlighted a tactical risk: a potential shift in geopolitical tensions, such as an Iran ceasefire, could trigger a rotation away from defence stocks back into broader economy-linked sectors.

Private Banks: A Constructive Turnaround Ahead

In contrast to the defence sector, Sabharwal views the private banking industry as one of the most constructive themes for the current market cycle. He expects the sector to benefit from strengthening credit growth and accelerating profitability.

Two major tailwinds are driving this optimism. First, the pressure on Net Interest Margins (NIMs) is easing as the RBI’s rate-cutting cycle stabilizes. Second, the anticipated influx of $50–$60 billion through FCNR (Foreign Currency Non-Resident) fundraising could provide a vital deposit pool to bridge the widening gap between credit and deposit growth. Within the sector, HDFC Bank is noted as a potential reversal candidate due to its recent underperformance, while ICICI Bank continues to show leadership. Kotak and Axis are also expected to participate in this recovery.

IT and Pharma: Attractive but Lacking Catalysts

The IT and Pharma sectors are characterized by stability rather than high-octane growth. The IT sector currently trades at attractive valuations of approximately 12–13 times one-year forward earnings. However, Sabharwal notes a lack of immediate triggers for a re-rating, a sentiment echoed by recent global trends. For contrarian investors, the sector could still offer 15–20% returns following a significant selloff.

In the Pharma space, large-cap players like Cipla, Dr. Reddy’s, and Sun Pharma are performing reasonably well with non-stretched valuations. However, the sector lacks a compelling new catalyst to drive massive rallies. While the Contract Development and Manufacturing Organization (CDMO) space is gaining buzz, the complexity of analyzing molecule-specific trends makes it a difficult area for rigorous evaluation.

Manufacturing and Chemicals: Winners and Losers

In manufacturing, Bharat Forge stands out due to its aggressive diversification into non-automotive segments. While power equipment companies maintain momentum, Sabharwal cautioned that names like Hitachi Energy and GE Vernova have reached valuations that are difficult to justify.

Furthermore, a warning was issued for companies linked to PVC and plastics. Due to a sharp crash in crude-linked chemical prices, firms that benefited from inventory gains last quarter are likely to face inventory losses this quarter, creating near-term caution for investors.

Key Takeaways

  • Defence Caution: Small-cap defence stocks face "obnoxious" P/E ratios of 100–200x, making them high-risk, though BEL remains a strong long-term pick.
  • Banking Optimism: Private banks are poised for a recovery driven by easing NIM pressures and the potential $50–$60 billion FCNR deposit influx.
  • Sectoral Lull: Both IT and Pharma offer reasonable valuations but currently lack the specific triggers required for a major market re-rating.